nodes	percent_of_prediction	percent_of_DWPC	metapath
Aclidinium—BCHE—Triamcinolone—hematologic cancer	0.125	0.421	CbGbCtD
Aclidinium—BCHE—Irinotecan—hematologic cancer	0.0947	0.319	CbGbCtD
Aclidinium—BCHE—Cisplatin—hematologic cancer	0.0772	0.26	CbGbCtD
Aclidinium—Headache—Pentostatin—hematologic cancer	0.00071	0.00137	CcSEcCtD
Aclidinium—Headache—Anagrelide—hematologic cancer	0.00071	0.00137	CcSEcCtD
Aclidinium—Mediastinal disorder—Irinotecan—hematologic cancer	0.000705	0.00136	CcSEcCtD
Aclidinium—Urinary tract disorder—Cisplatin—hematologic cancer	0.000702	0.00136	CcSEcCtD
Aclidinium—Urethral disorder—Cisplatin—hematologic cancer	0.000697	0.00135	CcSEcCtD
Aclidinium—Vomiting—Idarubicin—hematologic cancer	0.000695	0.00134	CcSEcCtD
Aclidinium—Cardiac failure—Prednisone—hematologic cancer	0.000691	0.00134	CcSEcCtD
Aclidinium—Vision blurred—Carmustine—hematologic cancer	0.000691	0.00134	CcSEcCtD
Aclidinium—Cough—Thiotepa—hematologic cancer	0.000689	0.00133	CcSEcCtD
Aclidinium—Mediastinal disorder—Gemcitabine—hematologic cancer	0.000687	0.00133	CcSEcCtD
Aclidinium—Infection—Bortezomib—hematologic cancer	0.000686	0.00133	CcSEcCtD
Aclidinium—Headache—Idarubicin—hematologic cancer	0.000685	0.00132	CcSEcCtD
Aclidinium—Vision blurred—Alitretinoin—hematologic cancer	0.000684	0.00132	CcSEcCtD
Aclidinium—Infection—Bleomycin—hematologic cancer	0.000681	0.00132	CcSEcCtD
Aclidinium—Nervous system disorder—Bortezomib—hematologic cancer	0.000677	0.00131	CcSEcCtD
Aclidinium—Vision blurred—Ifosfamide—hematologic cancer	0.000676	0.00131	CcSEcCtD
Aclidinium—Vomiting—Teniposide—hematologic cancer	0.000676	0.00131	CcSEcCtD
Aclidinium—Osteoarthritis—Prednisone—hematologic cancer	0.000675	0.0013	CcSEcCtD
Aclidinium—Diarrhoea—Busulfan—hematologic cancer	0.000674	0.0013	CcSEcCtD
Aclidinium—Tachycardia—Bortezomib—hematologic cancer	0.000674	0.0013	CcSEcCtD
Aclidinium—Infection—Vinorelbine—hematologic cancer	0.00067	0.0013	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Melphalan—hematologic cancer	0.000666	0.00129	CcSEcCtD
Aclidinium—Headache—Teniposide—hematologic cancer	0.000666	0.00129	CcSEcCtD
Aclidinium—Cough—Thalidomide—hematologic cancer	0.000666	0.00129	CcSEcCtD
Aclidinium—Eye disorder—Cisplatin—hematologic cancer	0.000664	0.00128	CcSEcCtD
Aclidinium—Nervous system disorder—Vinorelbine—hematologic cancer	0.000661	0.00128	CcSEcCtD
Aclidinium—Tachycardia—Vinorelbine—hematologic cancer	0.000658	0.00127	CcSEcCtD
Aclidinium—Diarrhoea—Procarbazine—hematologic cancer	0.000654	0.00127	CcSEcCtD
Aclidinium—Diabetes mellitus—Methotrexate—hematologic cancer	0.000648	0.00125	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Lenalidomide—hematologic cancer	0.000648	0.00125	CcSEcCtD
Aclidinium—Urinary tract disorder—Etoposide—hematologic cancer	0.000643	0.00124	CcSEcCtD
Aclidinium—Vision blurred—Mitoxantrone—hematologic cancer	0.000642	0.00124	CcSEcCtD
Aclidinium—Diarrhoea—Bexarotene—hematologic cancer	0.000641	0.00124	CcSEcCtD
Aclidinium—Diarrhoea—Dasatinib—hematologic cancer	0.000641	0.00124	CcSEcCtD
Aclidinium—Mediastinal disorder—Cisplatin—hematologic cancer	0.00064	0.00124	CcSEcCtD
Aclidinium—Infection—Thiotepa—hematologic cancer	0.00064	0.00124	CcSEcCtD
Aclidinium—Diarrhoea—Fludarabine—hematologic cancer	0.000639	0.00124	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Hydroxyurea—hematologic cancer	0.000639	0.00124	CcSEcCtD
Aclidinium—Urethral disorder—Etoposide—hematologic cancer	0.000638	0.00123	CcSEcCtD
Aclidinium—Dry mouth—Thalidomide—hematologic cancer	0.000635	0.00123	CcSEcCtD
Aclidinium—Cough—Alitretinoin—hematologic cancer	0.000634	0.00123	CcSEcCtD
Aclidinium—Nervous system disorder—Thiotepa—hematologic cancer	0.000632	0.00122	CcSEcCtD
Aclidinium—Tachycardia—Thiotepa—hematologic cancer	0.000628	0.00122	CcSEcCtD
Aclidinium—Vomiting—Busulfan—hematologic cancer	0.000627	0.00121	CcSEcCtD
Aclidinium—Cough—Ifosfamide—hematologic cancer	0.000626	0.00121	CcSEcCtD
Aclidinium—Infection—Thalidomide—hematologic cancer	0.000619	0.0012	CcSEcCtD
Aclidinium—Headache—Busulfan—hematologic cancer	0.000617	0.00119	CcSEcCtD
Aclidinium—Nervous system disorder—Thalidomide—hematologic cancer	0.000611	0.00118	CcSEcCtD
Aclidinium—Eye disorder—Etoposide—hematologic cancer	0.000608	0.00118	CcSEcCtD
Aclidinium—Vomiting—Procarbazine—hematologic cancer	0.000608	0.00118	CcSEcCtD
Aclidinium—Tachycardia—Thalidomide—hematologic cancer	0.000608	0.00118	CcSEcCtD
Aclidinium—Diabetes mellitus—Epirubicin—hematologic cancer	0.000607	0.00117	CcSEcCtD
Aclidinium—Diarrhoea—Chlorambucil—hematologic cancer	0.000606	0.00117	CcSEcCtD
Aclidinium—Dry mouth—Alitretinoin—hematologic cancer	0.000605	0.00117	CcSEcCtD
Aclidinium—Headache—Procarbazine—hematologic cancer	0.000599	0.00116	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Bortezomib—hematologic cancer	0.000596	0.00115	CcSEcCtD
Aclidinium—Vomiting—Bexarotene—hematologic cancer	0.000596	0.00115	CcSEcCtD
Aclidinium—Vomiting—Dasatinib—hematologic cancer	0.000596	0.00115	CcSEcCtD
Aclidinium—Cough—Mitoxantrone—hematologic cancer	0.000595	0.00115	CcSEcCtD
Aclidinium—Cough—Irinotecan—hematologic cancer	0.000595	0.00115	CcSEcCtD
Aclidinium—Infection—Carmustine—hematologic cancer	0.000594	0.00115	CcSEcCtD
Aclidinium—Vomiting—Fludarabine—hematologic cancer	0.000594	0.00115	CcSEcCtD
Aclidinium—Diarrhoea—Nilotinib—hematologic cancer	0.000592	0.00115	CcSEcCtD
Aclidinium—Rhinitis—Triamcinolone—hematologic cancer	0.000592	0.00115	CcSEcCtD
Aclidinium—Diarrhoea—Imatinib—hematologic cancer	0.000589	0.00114	CcSEcCtD
Aclidinium—Infection—Alitretinoin—hematologic cancer	0.000589	0.00114	CcSEcCtD
Aclidinium—Headache—Bexarotene—hematologic cancer	0.000587	0.00114	CcSEcCtD
Aclidinium—Headache—Dasatinib—hematologic cancer	0.000587	0.00114	CcSEcCtD
Aclidinium—Mediastinal disorder—Etoposide—hematologic cancer	0.000587	0.00113	CcSEcCtD
Aclidinium—Headache—Fludarabine—hematologic cancer	0.000586	0.00113	CcSEcCtD
Aclidinium—Tachycardia—Carmustine—hematologic cancer	0.000584	0.00113	CcSEcCtD
Aclidinium—Vision blurred—Cisplatin—hematologic cancer	0.000583	0.00113	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Vinorelbine—hematologic cancer	0.000582	0.00113	CcSEcCtD
Aclidinium—Infection—Ifosfamide—hematologic cancer	0.000582	0.00113	CcSEcCtD
Aclidinium—Nervous system disorder—Alitretinoin—hematologic cancer	0.000581	0.00112	CcSEcCtD
Aclidinium—Cough—Gemcitabine—hematologic cancer	0.000579	0.00112	CcSEcCtD
Aclidinium—Diarrhoea—Cladribine—hematologic cancer	0.000579	0.00112	CcSEcCtD
Aclidinium—Tachycardia—Alitretinoin—hematologic cancer	0.000578	0.00112	CcSEcCtD
Aclidinium—Nervous system disorder—Ifosfamide—hematologic cancer	0.000574	0.00111	CcSEcCtD
Aclidinium—Infection—Vincristine—hematologic cancer	0.000567	0.0011	CcSEcCtD
Aclidinium—Osteoarthritis—Methotrexate—hematologic cancer	0.000564	0.00109	CcSEcCtD
Aclidinium—Vomiting—Chlorambucil—hematologic cancer	0.000563	0.00109	CcSEcCtD
Aclidinium—Diabetes mellitus—Doxorubicin—hematologic cancer	0.000561	0.00109	CcSEcCtD
Aclidinium—Nervous system disorder—Vincristine—hematologic cancer	0.00056	0.00108	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Thiotepa—hematologic cancer	0.000556	0.00108	CcSEcCtD
Aclidinium—Diarrhoea—Vinblastine—hematologic cancer	0.000555	0.00107	CcSEcCtD
Aclidinium—Infection—Irinotecan—hematologic cancer	0.000552	0.00107	CcSEcCtD
Aclidinium—Infection—Mitoxantrone—hematologic cancer	0.000552	0.00107	CcSEcCtD
Aclidinium—Vomiting—Nilotinib—hematologic cancer	0.000551	0.00106	CcSEcCtD
Aclidinium—Vomiting—Imatinib—hematologic cancer	0.000547	0.00106	CcSEcCtD
Aclidinium—Nervous system disorder—Irinotecan—hematologic cancer	0.000545	0.00105	CcSEcCtD
Aclidinium—Tachycardia—Mitoxantrone—hematologic cancer	0.000543	0.00105	CcSEcCtD
Aclidinium—Headache—Nilotinib—hematologic cancer	0.000542	0.00105	CcSEcCtD
Aclidinium—Cardiac failure—Epirubicin—hematologic cancer	0.000541	0.00105	CcSEcCtD
Aclidinium—Headache—Imatinib—hematologic cancer	0.000539	0.00104	CcSEcCtD
Aclidinium—Infection—Gemcitabine—hematologic cancer	0.000538	0.00104	CcSEcCtD
Aclidinium—Vomiting—Cladribine—hematologic cancer	0.000538	0.00104	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Thalidomide—hematologic cancer	0.000538	0.00104	CcSEcCtD
Aclidinium—Nervous system disorder—Gemcitabine—hematologic cancer	0.000531	0.00103	CcSEcCtD
Aclidinium—Headache—Cladribine—hematologic cancer	0.00053	0.00103	CcSEcCtD
Aclidinium—Diarrhoea—Melphalan—hematologic cancer	0.000528	0.00102	CcSEcCtD
Aclidinium—Osteoarthritis—Epirubicin—hematologic cancer	0.000528	0.00102	CcSEcCtD
Aclidinium—Vision blurred—Prednisolone—hematologic cancer	0.000527	0.00102	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Carmustine—hematologic cancer	0.000516	0.000999	CcSEcCtD
Aclidinium—Vomiting—Vinblastine—hematologic cancer	0.000516	0.000998	CcSEcCtD
Aclidinium—Diarrhoea—Lenalidomide—hematologic cancer	0.000513	0.000993	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Alitretinoin—hematologic cancer	0.000512	0.000989	CcSEcCtD
Aclidinium—Headache—Vinblastine—hematologic cancer	0.000508	0.000983	CcSEcCtD
Aclidinium—Diarrhoea—Hydroxyurea—hematologic cancer	0.000506	0.000979	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Ifosfamide—hematologic cancer	0.000506	0.000978	CcSEcCtD
Aclidinium—Infection—Cisplatin—hematologic cancer	0.000502	0.00097	CcSEcCtD
Aclidinium—Eye disorder—Dexamethasone—hematologic cancer	0.000501	0.000968	CcSEcCtD
Aclidinium—Eye disorder—Betamethasone—hematologic cancer	0.000501	0.000968	CcSEcCtD
Aclidinium—Cardiac failure—Doxorubicin—hematologic cancer	0.0005	0.000967	CcSEcCtD
Aclidinium—Nervous system disorder—Cisplatin—hematologic cancer	0.000495	0.000958	CcSEcCtD
Aclidinium—Cough—Etoposide—hematologic cancer	0.000495	0.000957	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Vincristine—hematologic cancer	0.000493	0.000953	CcSEcCtD
Aclidinium—Tachycardia—Cisplatin—hematologic cancer	0.000493	0.000953	CcSEcCtD
Aclidinium—Vomiting—Melphalan—hematologic cancer	0.000491	0.000949	CcSEcCtD
Aclidinium—Osteoarthritis—Doxorubicin—hematologic cancer	0.000488	0.000944	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Irinotecan—hematologic cancer	0.00048	0.000929	CcSEcCtD
Aclidinium—Vomiting—Lenalidomide—hematologic cancer	0.000477	0.000923	CcSEcCtD
Aclidinium—Diarrhoea—Bortezomib—hematologic cancer	0.000472	0.000914	CcSEcCtD
Aclidinium—Nasopharyngitis—Epirubicin—hematologic cancer	0.000472	0.000912	CcSEcCtD
Aclidinium—Vomiting—Hydroxyurea—hematologic cancer	0.00047	0.00091	CcSEcCtD
Aclidinium—Headache—Lenalidomide—hematologic cancer	0.00047	0.000909	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Gemcitabine—hematologic cancer	0.000468	0.000904	CcSEcCtD
Aclidinium—Headache—Hydroxyurea—hematologic cancer	0.000464	0.000897	CcSEcCtD
Aclidinium—Diarrhoea—Vinorelbine—hematologic cancer	0.000461	0.000892	CcSEcCtD
Aclidinium—Infection—Etoposide—hematologic cancer	0.00046	0.000889	CcSEcCtD
Aclidinium—Tachycardia—Etoposide—hematologic cancer	0.000451	0.000873	CcSEcCtD
Aclidinium—Cough—Triamcinolone—hematologic cancer	0.000449	0.000868	CcSEcCtD
Aclidinium—Tachycardia—Prednisolone—hematologic cancer	0.000445	0.000861	CcSEcCtD
Aclidinium—Diarrhoea—Thiotepa—hematologic cancer	0.000441	0.000852	CcSEcCtD
Aclidinium—Vomiting—Bortezomib—hematologic cancer	0.000439	0.000849	CcSEcCtD
Aclidinium—Nasopharyngitis—Doxorubicin—hematologic cancer	0.000436	0.000844	CcSEcCtD
Aclidinium—Eye disorder—Prednisone—hematologic cancer	0.000436	0.000843	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Cisplatin—hematologic cancer	0.000436	0.000843	CcSEcCtD
Aclidinium—Vomiting—Bleomycin—hematologic cancer	0.000436	0.000843	CcSEcCtD
Aclidinium—Infestation NOS—Methotrexate—hematologic cancer	0.000434	0.00084	CcSEcCtD
Aclidinium—Infestation—Methotrexate—hematologic cancer	0.000434	0.00084	CcSEcCtD
Aclidinium—Headache—Bortezomib—hematologic cancer	0.000433	0.000837	CcSEcCtD
Aclidinium—Vomiting—Vinorelbine—hematologic cancer	0.000429	0.000829	CcSEcCtD
Aclidinium—Dry mouth—Triamcinolone—hematologic cancer	0.000428	0.000828	CcSEcCtD
Aclidinium—Diarrhoea—Thalidomide—hematologic cancer	0.000426	0.000824	CcSEcCtD
Aclidinium—Headache—Vinorelbine—hematologic cancer	0.000422	0.000817	CcSEcCtD
Aclidinium—Infection—Triamcinolone—hematologic cancer	0.000417	0.000806	CcSEcCtD
Aclidinium—Tachycardia—Triamcinolone—hematologic cancer	0.000409	0.000792	CcSEcCtD
Aclidinium—Vomiting—Thiotepa—hematologic cancer	0.000409	0.000792	CcSEcCtD
Aclidinium—Diarrhoea—Carmustine—hematologic cancer	0.000409	0.000792	CcSEcCtD
Aclidinium—Infestation—Epirubicin—hematologic cancer	0.000407	0.000786	CcSEcCtD
Aclidinium—Infestation NOS—Epirubicin—hematologic cancer	0.000407	0.000786	CcSEcCtD
Aclidinium—Diarrhoea—Alitretinoin—hematologic cancer	0.000405	0.000784	CcSEcCtD
Aclidinium—Headache—Thiotepa—hematologic cancer	0.000403	0.00078	CcSEcCtD
Aclidinium—Diarrhoea—Ifosfamide—hematologic cancer	0.000401	0.000775	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Etoposide—hematologic cancer	0.000399	0.000772	CcSEcCtD
Aclidinium—Vomiting—Thalidomide—hematologic cancer	0.000396	0.000766	CcSEcCtD
Aclidinium—Diarrhoea—Vincristine—hematologic cancer	0.000391	0.000756	CcSEcCtD
Aclidinium—Headache—Thalidomide—hematologic cancer	0.00039	0.000755	CcSEcCtD
Aclidinium—Urinary tract disorder—Methotrexate—hematologic cancer	0.000385	0.000745	CcSEcCtD
Aclidinium—Vision blurred—Prednisone—hematologic cancer	0.000383	0.00074	CcSEcCtD
Aclidinium—Urethral disorder—Methotrexate—hematologic cancer	0.000382	0.000739	CcSEcCtD
Aclidinium—Sinusitis—Epirubicin—hematologic cancer	0.000381	0.000738	CcSEcCtD
Aclidinium—Diarrhoea—Mitoxantrone—hematologic cancer	0.00038	0.000736	CcSEcCtD
Aclidinium—Diarrhoea—Irinotecan—hematologic cancer	0.00038	0.000736	CcSEcCtD
Aclidinium—Vomiting—Carmustine—hematologic cancer	0.00038	0.000736	CcSEcCtD
Aclidinium—Infection—Betamethasone—hematologic cancer	0.000378	0.000731	CcSEcCtD
Aclidinium—Infection—Dexamethasone—hematologic cancer	0.000378	0.000731	CcSEcCtD
Aclidinium—Vomiting—Alitretinoin—hematologic cancer	0.000377	0.000729	CcSEcCtD
Aclidinium—Infestation NOS—Doxorubicin—hematologic cancer	0.000376	0.000728	CcSEcCtD
Aclidinium—Infestation—Doxorubicin—hematologic cancer	0.000376	0.000728	CcSEcCtD
Aclidinium—Headache—Carmustine—hematologic cancer	0.000375	0.000725	CcSEcCtD
Aclidinium—Nervous system disorder—Dexamethasone—hematologic cancer	0.000373	0.000722	CcSEcCtD
Aclidinium—Nervous system disorder—Betamethasone—hematologic cancer	0.000373	0.000722	CcSEcCtD
Aclidinium—Vomiting—Ifosfamide—hematologic cancer	0.000372	0.00072	CcSEcCtD
Aclidinium—Tachycardia—Dexamethasone—hematologic cancer	0.000372	0.000719	CcSEcCtD
Aclidinium—Tachycardia—Betamethasone—hematologic cancer	0.000372	0.000719	CcSEcCtD
Aclidinium—Headache—Alitretinoin—hematologic cancer	0.000371	0.000718	CcSEcCtD
Aclidinium—Diarrhoea—Gemcitabine—hematologic cancer	0.000371	0.000717	CcSEcCtD
Aclidinium—Rhinitis—Epirubicin—hematologic cancer	0.000366	0.000708	CcSEcCtD
Aclidinium—Eye disorder—Methotrexate—hematologic cancer	0.000364	0.000705	CcSEcCtD
Aclidinium—Vomiting—Vincristine—hematologic cancer	0.000363	0.000702	CcSEcCtD
Aclidinium—Urinary tract disorder—Epirubicin—hematologic cancer	0.00036	0.000697	CcSEcCtD
Aclidinium—Urethral disorder—Epirubicin—hematologic cancer	0.000358	0.000692	CcSEcCtD
Aclidinium—Headache—Vincristine—hematologic cancer	0.000358	0.000692	CcSEcCtD
Aclidinium—Vomiting—Mitoxantrone—hematologic cancer	0.000354	0.000684	CcSEcCtD
Aclidinium—Vomiting—Irinotecan—hematologic cancer	0.000354	0.000684	CcSEcCtD
Aclidinium—Sinusitis—Doxorubicin—hematologic cancer	0.000353	0.000683	CcSEcCtD
Aclidinium—Mediastinal disorder—Methotrexate—hematologic cancer	0.000351	0.00068	CcSEcCtD
Aclidinium—Headache—Mitoxantrone—hematologic cancer	0.000348	0.000674	CcSEcCtD
Aclidinium—Headache—Irinotecan—hematologic cancer	0.000348	0.000674	CcSEcCtD
Aclidinium—Diarrhoea—Cisplatin—hematologic cancer	0.000345	0.000668	CcSEcCtD
Aclidinium—Vomiting—Gemcitabine—hematologic cancer	0.000344	0.000666	CcSEcCtD
Aclidinium—Eye disorder—Epirubicin—hematologic cancer	0.000341	0.00066	CcSEcCtD
Aclidinium—Headache—Gemcitabine—hematologic cancer	0.000339	0.000656	CcSEcCtD
Aclidinium—Rhinitis—Doxorubicin—hematologic cancer	0.000339	0.000655	CcSEcCtD
Aclidinium—Urinary tract disorder—Doxorubicin—hematologic cancer	0.000333	0.000645	CcSEcCtD
Aclidinium—Urethral disorder—Doxorubicin—hematologic cancer	0.000331	0.00064	CcSEcCtD
Aclidinium—Infection—Prednisone—hematologic cancer	0.000329	0.000637	CcSEcCtD
Aclidinium—Mediastinal disorder—Epirubicin—hematologic cancer	0.000329	0.000636	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Betamethasone—hematologic cancer	0.000329	0.000636	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Dexamethasone—hematologic cancer	0.000329	0.000636	CcSEcCtD
Aclidinium—Nervous system disorder—Prednisone—hematologic cancer	0.000325	0.000629	CcSEcCtD
Aclidinium—Tachycardia—Prednisone—hematologic cancer	0.000324	0.000626	CcSEcCtD
Aclidinium—Vomiting—Cisplatin—hematologic cancer	0.000321	0.000621	CcSEcCtD
Aclidinium—Vision blurred—Methotrexate—hematologic cancer	0.00032	0.000619	CcSEcCtD
Aclidinium—Diarrhoea—Etoposide—hematologic cancer	0.000316	0.000612	CcSEcCtD
Aclidinium—Eye disorder—Doxorubicin—hematologic cancer	0.000316	0.00061	CcSEcCtD
Aclidinium—Mediastinal disorder—Doxorubicin—hematologic cancer	0.000304	0.000589	CcSEcCtD
Aclidinium—Vision blurred—Epirubicin—hematologic cancer	0.000299	0.000579	CcSEcCtD
Aclidinium—Cough—Methotrexate—hematologic cancer	0.000296	0.000573	CcSEcCtD
Aclidinium—Vomiting—Etoposide—hematologic cancer	0.000294	0.000569	CcSEcCtD
Aclidinium—Headache—Etoposide—hematologic cancer	0.00029	0.00056	CcSEcCtD
Aclidinium—Headache—Prednisolone—hematologic cancer	0.000286	0.000553	CcSEcCtD
Aclidinium—Cough—Epirubicin—hematologic cancer	0.000277	0.000536	CcSEcCtD
Aclidinium—Vision blurred—Doxorubicin—hematologic cancer	0.000277	0.000536	CcSEcCtD
Aclidinium—Infection—Methotrexate—hematologic cancer	0.000275	0.000532	CcSEcCtD
Aclidinium—Nervous system disorder—Methotrexate—hematologic cancer	0.000272	0.000525	CcSEcCtD
Aclidinium—Vomiting—Triamcinolone—hematologic cancer	0.000267	0.000516	CcSEcCtD
Aclidinium—Dry mouth—Epirubicin—hematologic cancer	0.000265	0.000512	CcSEcCtD
Aclidinium—Headache—Triamcinolone—hematologic cancer	0.000263	0.000508	CcSEcCtD
Aclidinium—Diarrhoea—Dexamethasone—hematologic cancer	0.00026	0.000504	CcSEcCtD
Aclidinium—Diarrhoea—Betamethasone—hematologic cancer	0.00026	0.000504	CcSEcCtD
Aclidinium—Infection—Epirubicin—hematologic cancer	0.000258	0.000498	CcSEcCtD
Aclidinium—Cough—Doxorubicin—hematologic cancer	0.000257	0.000496	CcSEcCtD
Aclidinium—Nervous system disorder—Epirubicin—hematologic cancer	0.000254	0.000492	CcSEcCtD
Aclidinium—Tachycardia—Epirubicin—hematologic cancer	0.000253	0.000489	CcSEcCtD
Aclidinium—Dry mouth—Doxorubicin—hematologic cancer	0.000245	0.000473	CcSEcCtD
Aclidinium—Vomiting—Betamethasone—hematologic cancer	0.000242	0.000468	CcSEcCtD
Aclidinium—Vomiting—Dexamethasone—hematologic cancer	0.000242	0.000468	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Methotrexate—hematologic cancer	0.000239	0.000463	CcSEcCtD
Aclidinium—Headache—Betamethasone—hematologic cancer	0.000238	0.000461	CcSEcCtD
Aclidinium—Headache—Dexamethasone—hematologic cancer	0.000238	0.000461	CcSEcCtD
Aclidinium—Infection—Doxorubicin—hematologic cancer	0.000238	0.000461	CcSEcCtD
Aclidinium—Nervous system disorder—Doxorubicin—hematologic cancer	0.000235	0.000455	CcSEcCtD
Aclidinium—Tachycardia—Doxorubicin—hematologic cancer	0.000234	0.000453	CcSEcCtD
Aclidinium—Diarrhoea—Prednisone—hematologic cancer	0.000227	0.000439	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Epirubicin—hematologic cancer	0.000224	0.000433	CcSEcCtD
Aclidinium—Vomiting—Prednisone—hematologic cancer	0.000211	0.000408	CcSEcCtD
Aclidinium—Headache—Prednisone—hematologic cancer	0.000208	0.000402	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Doxorubicin—hematologic cancer	0.000207	0.000401	CcSEcCtD
Aclidinium—Diarrhoea—Methotrexate—hematologic cancer	0.00019	0.000367	CcSEcCtD
Aclidinium—Diarrhoea—Epirubicin—hematologic cancer	0.000177	0.000343	CcSEcCtD
Aclidinium—Vomiting—Methotrexate—hematologic cancer	0.000176	0.000341	CcSEcCtD
Aclidinium—Headache—Methotrexate—hematologic cancer	0.000174	0.000336	CcSEcCtD
Aclidinium—Vomiting—Epirubicin—hematologic cancer	0.000165	0.000319	CcSEcCtD
Aclidinium—Diarrhoea—Doxorubicin—hematologic cancer	0.000164	0.000317	CcSEcCtD
Aclidinium—Headache—Epirubicin—hematologic cancer	0.000162	0.000314	CcSEcCtD
Aclidinium—Vomiting—Doxorubicin—hematologic cancer	0.000153	0.000295	CcSEcCtD
Aclidinium—Headache—Doxorubicin—hematologic cancer	0.00015	0.000291	CcSEcCtD
Aclidinium—CHRM2—Signaling Pathways—IL2RA—hematologic cancer	1.8e-05	9.66e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—TERT—hematologic cancer	1.8e-05	9.65e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—PIK3R1—hematologic cancer	1.79e-05	9.61e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—IL2—hematologic cancer	1.78e-05	9.59e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling by GPCR—PIK3CA—hematologic cancer	1.78e-05	9.56e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—TERT—hematologic cancer	1.78e-05	9.55e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—MDM2—hematologic cancer	1.77e-05	9.52e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—PDGFB—hematologic cancer	1.76e-05	9.45e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—PDGFB—hematologic cancer	1.75e-05	9.42e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—JAK2—hematologic cancer	1.74e-05	9.34e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—PDGFB—hematologic cancer	1.74e-05	9.32e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—MTOR—hematologic cancer	1.72e-05	9.27e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—PIK3CB—hematologic cancer	1.72e-05	9.27e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—TSC2—hematologic cancer	1.72e-05	9.23e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—TSC2—hematologic cancer	1.71e-05	9.2e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling by GPCR—PIK3CA—hematologic cancer	1.7e-05	9.16e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—MDM2—hematologic cancer	1.7e-05	9.12e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—TSC2—hematologic cancer	1.7e-05	9.11e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—CREBBP—hematologic cancer	1.68e-05	9.01e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—FGFR3—hematologic cancer	1.65e-05	8.88e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—MTOR—hematologic cancer	1.65e-05	8.87e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—PIK3CB—hematologic cancer	1.65e-05	8.87e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—FGFR3—hematologic cancer	1.65e-05	8.85e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling by GPCR—HRAS—hematologic cancer	1.65e-05	8.85e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—MAPK14—hematologic cancer	1.64e-05	8.79e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—FGFR3—hematologic cancer	1.63e-05	8.77e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—MAPK14—hematologic cancer	1.63e-05	8.76e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—CDKN1B—hematologic cancer	1.62e-05	8.7e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—MAPK14—hematologic cancer	1.62e-05	8.68e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—ESR1—hematologic cancer	1.61e-05	8.63e-05	CbGpPWpGaD
Aclidinium—CHRM4—GPCR downstream signaling—AKT1—hematologic cancer	1.6e-05	8.6e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—ESR1—hematologic cancer	1.6e-05	8.6e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—PIK3CD—hematologic cancer	1.59e-05	8.54e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—CASP3—hematologic cancer	1.59e-05	8.52e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—FN1—hematologic cancer	1.59e-05	8.52e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—ESR1—hematologic cancer	1.58e-05	8.51e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—IL2—hematologic cancer	1.58e-05	8.51e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—FN1—hematologic cancer	1.58e-05	8.49e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling by GPCR—HRAS—hematologic cancer	1.58e-05	8.47e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling by GPCR—IL6—hematologic cancer	1.58e-05	8.47e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—ALB—hematologic cancer	1.57e-05	8.44e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—NFKBIA—hematologic cancer	1.57e-05	8.42e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—BAD—hematologic cancer	1.57e-05	8.42e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—FN1—hematologic cancer	1.57e-05	8.41e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—BAD—hematologic cancer	1.56e-05	8.39e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—NFKBIA—hematologic cancer	1.56e-05	8.39e-05	CbGpPWpGaD
Aclidinium—BCHE—Metabolism—PTEN—hematologic cancer	1.56e-05	8.37e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—NOTCH1—hematologic cancer	1.55e-05	8.34e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—CDKN1B—hematologic cancer	1.55e-05	8.33e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—NOTCH1—hematologic cancer	1.55e-05	8.31e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—BAD—hematologic cancer	1.55e-05	8.31e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—NFKBIA—hematologic cancer	1.55e-05	8.31e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—CCND1—hematologic cancer	1.54e-05	8.3e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—JUN—hematologic cancer	1.54e-05	8.28e-05	CbGpPWpGaD
Aclidinium—CHRM5—GPCR downstream signaling—AKT1—hematologic cancer	1.53e-05	8.24e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—NOTCH1—hematologic cancer	1.53e-05	8.23e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CD80—hematologic cancer	1.52e-05	8.17e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—CASP3—hematologic cancer	1.52e-05	8.16e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—KIT—hematologic cancer	1.52e-05	8.15e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—PIK3CG—hematologic cancer	1.52e-05	8.15e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—NRAS—hematologic cancer	1.52e-05	8.15e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—IL2—hematologic cancer	1.52e-05	8.15e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CD80—hematologic cancer	1.52e-05	8.14e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—PIK3CG—hematologic cancer	1.51e-05	8.13e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—KIT—hematologic cancer	1.51e-05	8.13e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—NRAS—hematologic cancer	1.51e-05	8.13e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling by GPCR—IL6—hematologic cancer	1.51e-05	8.11e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—PIK3R1—hematologic cancer	1.5e-05	8.07e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CD80—hematologic cancer	1.5e-05	8.06e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—KIT—hematologic cancer	1.5e-05	8.05e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—PIK3CG—hematologic cancer	1.5e-05	8.05e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—NRAS—hematologic cancer	1.5e-05	8.05e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—CDKN1A—hematologic cancer	1.49e-05	8.02e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—PTPN11—hematologic cancer	1.49e-05	8.01e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—PTEN—hematologic cancer	1.49e-05	8.01e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—PTPN11—hematologic cancer	1.49e-05	7.98e-05	CbGpPWpGaD
Aclidinium—BCHE—Metabolism—EP300—hematologic cancer	1.49e-05	7.98e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—CCND1—hematologic cancer	1.48e-05	7.94e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—JUN—hematologic cancer	1.48e-05	7.93e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—PTPN11—hematologic cancer	1.47e-05	7.91e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—MAPK8—hematologic cancer	1.46e-05	7.83e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling by GPCR—AKT1—hematologic cancer	1.45e-05	7.81e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—MAPK3—hematologic cancer	1.45e-05	7.81e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—MAPK3—hematologic cancer	1.45e-05	7.78e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CREB1—hematologic cancer	1.44e-05	7.76e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CREB1—hematologic cancer	1.44e-05	7.74e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—MAPK3—hematologic cancer	1.43e-05	7.71e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—CDKN1A—hematologic cancer	1.43e-05	7.68e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—PTEN—hematologic cancer	1.43e-05	7.67e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—BRAF—hematologic cancer	1.43e-05	7.66e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CREB1—hematologic cancer	1.43e-05	7.66e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—BRAF—hematologic cancer	1.42e-05	7.64e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—EP300—hematologic cancer	1.42e-05	7.64e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CCL2—hematologic cancer	1.41e-05	7.59e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—IL6R—hematologic cancer	1.41e-05	7.57e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CCL2—hematologic cancer	1.41e-05	7.57e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—BRAF—hematologic cancer	1.41e-05	7.57e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CREBBP—hematologic cancer	1.41e-05	7.56e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—IL6R—hematologic cancer	1.4e-05	7.55e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CREBBP—hematologic cancer	1.4e-05	7.54e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—MAPK8—hematologic cancer	1.4e-05	7.5e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CCL2—hematologic cancer	1.4e-05	7.5e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling by GPCR—AKT1—hematologic cancer	1.39e-05	7.48e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—IL6R—hematologic cancer	1.39e-05	7.47e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CREBBP—hematologic cancer	1.39e-05	7.46e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—PIK3CB—hematologic cancer	1.39e-05	7.45e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—SRC—hematologic cancer	1.38e-05	7.43e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—EP300—hematologic cancer	1.36e-05	7.31e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—VEGFA—hematologic cancer	1.35e-05	7.23e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—MAP2K1—hematologic cancer	1.34e-05	7.22e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—MAP2K1—hematologic cancer	1.34e-05	7.19e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—PIK3CD—hematologic cancer	1.33e-05	7.17e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—STAT3—hematologic cancer	1.33e-05	7.16e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—PIK3CD—hematologic cancer	1.33e-05	7.14e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—NRAS—hematologic cancer	1.33e-05	7.14e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—MAP2K1—hematologic cancer	1.33e-05	7.12e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—SRC—hematologic cancer	1.32e-05	7.11e-05	CbGpPWpGaD
Aclidinium—CHRM1—GPCR downstream signaling—PIK3CA—hematologic cancer	1.32e-05	7.1e-05	CbGpPWpGaD
Aclidinium—CHRM3—GPCR downstream signaling—PIK3CA—hematologic cancer	1.32e-05	7.08e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—PIK3CD—hematologic cancer	1.32e-05	7.08e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—KRAS—hematologic cancer	1.31e-05	7.02e-05	CbGpPWpGaD
Aclidinium—CHRM2—GPCR downstream signaling—PIK3CA—hematologic cancer	1.3e-05	7.01e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—KRAS—hematologic cancer	1.3e-05	7e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—KRAS—hematologic cancer	1.29e-05	6.93e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—VEGFA—hematologic cancer	1.29e-05	6.93e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—FGF2—hematologic cancer	1.28e-05	6.86e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—STAT3—hematologic cancer	1.28e-05	6.86e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—MAPK3—hematologic cancer	1.27e-05	6.84e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—FGF2—hematologic cancer	1.27e-05	6.84e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—NRAS—hematologic cancer	1.27e-05	6.84e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—FGF2—hematologic cancer	1.26e-05	6.77e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—PIK3R1—hematologic cancer	1.26e-05	6.77e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—PIK3R1—hematologic cancer	1.26e-05	6.75e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—PIK3R1—hematologic cancer	1.24e-05	6.68e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—MYC—hematologic cancer	1.24e-05	6.65e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—TGFB1—hematologic cancer	1.24e-05	6.64e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—JAK2—hematologic cancer	1.22e-05	6.58e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—JAK2—hematologic cancer	1.22e-05	6.56e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—MAPK3—hematologic cancer	1.22e-05	6.55e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—JAK2—hematologic cancer	1.21e-05	6.49e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—PIK3CA—hematologic cancer	1.2e-05	6.45e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—PTEN—hematologic cancer	1.2e-05	6.44e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—PIK3CA—hematologic cancer	1.2e-05	6.43e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—MDM2—hematologic cancer	1.2e-05	6.42e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—MDM2—hematologic cancer	1.19e-05	6.4e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—MYC—hematologic cancer	1.19e-05	6.37e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—PIK3CA—hematologic cancer	1.18e-05	6.36e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—TGFB1—hematologic cancer	1.18e-05	6.36e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—MDM2—hematologic cancer	1.18e-05	6.34e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—MTOR—hematologic cancer	1.16e-05	6.25e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—PIK3CB—hematologic cancer	1.16e-05	6.25e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—MTOR—hematologic cancer	1.16e-05	6.23e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—PIK3CB—hematologic cancer	1.16e-05	6.23e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—MTOR—hematologic cancer	1.15e-05	6.17e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—PIK3CB—hematologic cancer	1.15e-05	6.17e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—KRAS—hematologic cancer	1.14e-05	6.15e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—EP300—hematologic cancer	1.14e-05	6.14e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—HRAS—hematologic cancer	1.11e-05	5.96e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—HRAS—hematologic cancer	1.11e-05	5.95e-05	CbGpPWpGaD
Aclidinium—BCHE—Metabolism—PIK3CA—hematologic cancer	1.1e-05	5.9e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—HRAS—hematologic cancer	1.1e-05	5.89e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—KRAS—hematologic cancer	1.1e-05	5.89e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CDKN1B—hematologic cancer	1.09e-05	5.86e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CDKN1B—hematologic cancer	1.09e-05	5.84e-05	CbGpPWpGaD
Aclidinium—CHRM1—GPCR downstream signaling—AKT1—hematologic cancer	1.08e-05	5.8e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CDKN1B—hematologic cancer	1.08e-05	5.79e-05	CbGpPWpGaD
Aclidinium—CHRM3—GPCR downstream signaling—AKT1—hematologic cancer	1.08e-05	5.78e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CASP3—hematologic cancer	1.07e-05	5.75e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—IL2—hematologic cancer	1.07e-05	5.74e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CASP3—hematologic cancer	1.07e-05	5.73e-05	CbGpPWpGaD
Aclidinium—CHRM2—GPCR downstream signaling—AKT1—hematologic cancer	1.07e-05	5.73e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—IL2—hematologic cancer	1.06e-05	5.72e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—IL6—hematologic cancer	1.06e-05	5.71e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—IL6—hematologic cancer	1.06e-05	5.69e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CASP3—hematologic cancer	1.06e-05	5.67e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—IL2—hematologic cancer	1.05e-05	5.66e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—PIK3CA—hematologic cancer	1.05e-05	5.65e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—IL6—hematologic cancer	1.05e-05	5.64e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CCND1—hematologic cancer	1.04e-05	5.59e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—JUN—hematologic cancer	1.04e-05	5.58e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CCND1—hematologic cancer	1.04e-05	5.58e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—JUN—hematologic cancer	1.04e-05	5.56e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CCND1—hematologic cancer	1.03e-05	5.52e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—JUN—hematologic cancer	1.03e-05	5.51e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—TP53—hematologic cancer	1.02e-05	5.46e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CDKN1A—hematologic cancer	1.01e-05	5.41e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—PIK3CA—hematologic cancer	1.01e-05	5.41e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—PTEN—hematologic cancer	1e-05	5.4e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CDKN1A—hematologic cancer	1e-05	5.39e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—PTEN—hematologic cancer	1e-05	5.38e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CDKN1A—hematologic cancer	9.94e-06	5.34e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—PTEN—hematologic cancer	9.92e-06	5.33e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—MAPK8—hematologic cancer	9.83e-06	5.28e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—AKT1—hematologic cancer	9.8e-06	5.27e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—MAPK8—hematologic cancer	9.8e-06	5.26e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—AKT1—hematologic cancer	9.77e-06	5.25e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—TP53—hematologic cancer	9.74e-06	5.23e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—HRAS—hematologic cancer	9.73e-06	5.23e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—MAPK8—hematologic cancer	9.7e-06	5.21e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—AKT1—hematologic cancer	9.68e-06	5.2e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—EP300—hematologic cancer	9.58e-06	5.15e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—EP300—hematologic cancer	9.55e-06	5.13e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—EP300—hematologic cancer	9.46e-06	5.08e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—SRC—hematologic cancer	9.32e-06	5.01e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—HRAS—hematologic cancer	9.31e-06	5e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—IL6—hematologic cancer	9.31e-06	5e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—SRC—hematologic cancer	9.29e-06	4.99e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—SRC—hematologic cancer	9.2e-06	4.94e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—VEGFA—hematologic cancer	9.07e-06	4.88e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—VEGFA—hematologic cancer	9.05e-06	4.86e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—STAT3—hematologic cancer	8.99e-06	4.83e-05	CbGpPWpGaD
Aclidinium—BCHE—Metabolism—AKT1—hematologic cancer	8.98e-06	4.82e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—NRAS—hematologic cancer	8.96e-06	4.82e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—VEGFA—hematologic cancer	8.96e-06	4.81e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—STAT3—hematologic cancer	8.96e-06	4.81e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—NRAS—hematologic cancer	8.93e-06	4.8e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—IL6—hematologic cancer	8.91e-06	4.79e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—STAT3—hematologic cancer	8.87e-06	4.77e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—NRAS—hematologic cancer	8.85e-06	4.75e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—AKT1—hematologic cancer	8.59e-06	4.61e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—MAPK3—hematologic cancer	8.58e-06	4.61e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—MAPK3—hematologic cancer	8.56e-06	4.6e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—MAPK3—hematologic cancer	8.47e-06	4.55e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—PIK3CA—hematologic cancer	8.45e-06	4.54e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—MYC—hematologic cancer	8.35e-06	4.49e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—TGFB1—hematologic cancer	8.33e-06	4.48e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—MYC—hematologic cancer	8.32e-06	4.47e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—TGFB1—hematologic cancer	8.3e-06	4.46e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—MYC—hematologic cancer	8.24e-06	4.43e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—AKT1—hematologic cancer	8.22e-06	4.42e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—TGFB1—hematologic cancer	8.22e-06	4.42e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—KRAS—hematologic cancer	7.71e-06	4.15e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—KRAS—hematologic cancer	7.69e-06	4.13e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—KRAS—hematologic cancer	7.62e-06	4.09e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—PIK3CA—hematologic cancer	7.09e-06	3.81e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—PIK3CA—hematologic cancer	7.07e-06	3.8e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—PIK3CA—hematologic cancer	7e-06	3.76e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—AKT1—hematologic cancer	6.9e-06	3.71e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—TP53—hematologic cancer	6.86e-06	3.68e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—TP53—hematologic cancer	6.83e-06	3.67e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—TP53—hematologic cancer	6.77e-06	3.64e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—HRAS—hematologic cancer	6.56e-06	3.52e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—HRAS—hematologic cancer	6.54e-06	3.51e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—HRAS—hematologic cancer	6.47e-06	3.48e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—IL6—hematologic cancer	6.28e-06	3.37e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—IL6—hematologic cancer	6.26e-06	3.36e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—IL6—hematologic cancer	6.2e-06	3.33e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—AKT1—hematologic cancer	5.79e-06	3.11e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—AKT1—hematologic cancer	5.77e-06	3.1e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—AKT1—hematologic cancer	5.72e-06	3.07e-05	CbGpPWpGaD
